News
PBLA
0.011
NaN%
--
Weekly Report: what happened at PBLA last week (0601-0605)?
Weekly Report · 1d ago
Weekly Report: what happened at PBLA last week (0525-0529)?
Weekly Report · 06/01 10:26
Weekly Report: what happened at PBLA last week (0518-0522)?
Weekly Report · 05/25 10:30
Weekly Report: what happened at PBLA last week (0511-0515)?
Weekly Report · 05/18 10:30
Weekly Report: what happened at PBLA last week (0504-0508)?
Weekly Report · 05/11 10:26
Weekly Report: what happened at PBLA last week (0427-0501)?
Weekly Report · 05/04 10:24
Weekly Report: what happened at PBLA last week (0420-0424)?
Weekly Report · 04/27 10:27
Weekly Report: what happened at PBLA last week (0413-0417)?
Weekly Report · 04/20 10:22
Weekly Report: what happened at PBLA last week (0406-0410)?
Weekly Report · 04/13 10:27
Weekly Report: what happened at PBLA last week (0330-0403)?
Weekly Report · 04/06 10:27
Weekly Report: what happened at PBLA last week (0323-0327)?
Weekly Report · 03/30 10:27
Weekly Report: what happened at PBLA last week (0316-0320)?
Weekly Report · 03/23 10:24
Weekly Report: what happened at PBLA last week (0309-0313)?
Weekly Report · 03/16 10:23
Weekly Report: what happened at PBLA last week (0302-0306)?
Weekly Report · 03/09 10:23
Weekly Report: what happened at PBLA last week (0223-0227)?
Weekly Report · 03/02 10:22
Weekly Report: what happened at PBLA last week (0216-0220)?
Weekly Report · 02/23 10:22
Weekly Report: what happened at PBLA last week (0209-0213)?
Weekly Report · 02/16 10:22
Weekly Report: what happened at PBLA last week (0202-0206)?
Weekly Report · 02/09 10:23
Weekly Report: what happened at PBLA last week (0126-0130)?
Weekly Report · 02/02 10:23
Weekly Report: what happened at PBLA last week (0119-0123)?
Weekly Report · 01/26 10:23
More
Webull provides a variety of real-time PBLA stock news. You can receive the latest news about Panbela Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PBLA
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company’s lead candidates are ivospemin (SBP-101), for which it has licensed the worldwide rights from the University of Florida Research Foundation, Inc., Flynpovi, a combination of eflornithine (CPP-1X) and sulindac and eflornithine (CPP-1X), alone in tablet or sachet form. It has licensed rights from the Arizona Board of Regents of the University of Arizona to commercialize Flynpovi. Additionally, eflornithine is being evaluated with high dose testosterone and enzalutamide in metastatic castration-resistant prostate cancer in a phase II trial. The Company is engaged in over two sponsored research agreements to evaluate the polyamines individually and combined for various diseases.